Please Wait.....
Report
Saudi Arabia Generic Drugs Market Assessment, By Application [Neurovascular, Cardiovascular, Dermatology, Oncology, Diabetology, Respiratory, Others], By Type [Biosimilar Generics, Small Molecule Generics], By Brand [Branded Generic, Pure Generic], By Route of Administration [Oral, Injectable, Topical, Others], By Distribution Channel [Hospital Pharmacy, Retail Pharmacy, Online Pharmacy], By Region, Opportunities and Forecast, 2017-2031F
Market Report I 2024-09-30 I 121 Pages I Market Xcel - Markets and Data
Saudi Arabia generic drugs market is projected to witness a CAGR of 7.18% during the forecast period 2024-2031, growing from USD 4.38 billion in 2023 to USD 7.62 billion in 2031. The growth of the market is supported by the rising cases of chronic diseases, increasing government initiatives, and rising investments by the key market players towards collaborations to support the introduction of various biosimilars in the country.
Implementing various measures to facilitate the availability of generic alternatives in the country after the expiration of patents fosters affordability and competition in Saudi Arabia. The country's healthcare system aims to provide effective therapeutic solutions to patients while ensuring cost efficiency by encouraging the adoption of generic drugs, thus providing lucrative growth opportunities to the market. The growing efforts of the government to boost awareness about the different benefits associated with generic drugs are also providing lucrative growth opportunities to the market. They contain the same active ingredient, route of administration, strength, and dosage form as their brand name counterparts and offer cost efficiency to the patient.
Additionally, the growing prevalence of various chronic diseases and infectious diseases, and genetic disorders in different regions across Saudi Arabia is propelling the requirement for effective and safe medications in the country, thus bolstering the market's demand. According to the estimates of the International Diabetes Federation (IDF), approximately 5.6 million individuals will be living with diabetes in Saudi Arabia by 2030.
Government Initiatives Support Market Expansion
The growing popularity of generic drugs in Saudi Arabia can be attributed to the introduction of supportive government initiatives and policies to boost the affordability and accessibility of healthcare services in the country. The dedicated efforts of the country to support the growth of the pharmaceutical sector, in combination with their efforts to increase public awareness, are propelling the demand for generic drugs. Additionally, the introduction of initiatives such as the Healthcare Sector Transformation Program supports the development of an enhanced system that prioritizes disease prevention, innovation, and financial sustainability while enhancing patient access to healthcare services, supporting market growth.
Rising Prevalence of Chronic Diseases Boosts Market Demand
The rising cases of cardiovascular diseases in the country are propelling the market demand. According to a report published in February 2023 by the Ministry of Health of Saudi Arabia, cardiovascular diseases are the leading cause of deaths that occur because of non-communicable diseases in Saudi Arabia. Furthermore, the Journal of the Saudi Heart Association 2023 also estimates that the current prevalence of cardiovascular diseases is expected to be significantly higher due to the growth of the risk factors associated with cardiovascular diseases in the country, including hypertension, obesity, dyslipidemia, and diabetes mellitus. The adoption of a sedentary lifestyle by the Saudi Arabian population due to the growing influence of video games and social media and the environment of the country that limits outdoor activities is also propelling the cases of cardiovascular diseases in the country and supporting the market's expansion.
Biosimilars Account for Major Market Share
The rising efforts by key market players to increase the availability of various generics in the country are boosting Saudi Arabia's generic drugs market size and supporting the growth of the segment. In November 2023, Lupin Ltd., one of the leading transnational pharmaceutical companies across the globe, announced a partnership with Amman Pharmaceuticals Industries for exclusive commercialization and marketing of Ranibizumab in the Middle East region, including select territories of Lebanon, Saudi Arabia, UAE, Iraq, and Jordan, among other GCC countries. Ranibizumab inhibits and binds vascular endothelial growth factor A and is indicated for treating patients with macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, diabetic macular edema, and neovascular (wet) age-related macular degeneration. Such efforts and collaborations are expected to provide lucrative growth opportunities for the market in the coming years.
Future Market Scenario (2024-2031F)
As per the Saudi Arabia generic drugs market analysis, the increasing cases of chronic diseases and rising efforts of the government to transform the healthcare sector and boost awareness about the quality and effectiveness of generic drugs among the population are expected to support the growth of the market. According to the estimates of the International IDF, approximately 7.5 million individuals will be living with diabetes in Saudi Arabia by 2045. Strategic collaborations by the key players of the market to boost the availability of biosimilars in the country are also expected to provide lucrative growth opportunities to the market in the coming years. Initiatives such as Vision 2030, which aims to improve the quality of life of the residents of the country by supporting global integration, boosting opportunities for growth and investment, and enhancing the efficiency of the government, are expected to support the market's expansion in Saudi Arabia.
Key Players Landscape and Outlook
The rising collaborations and partnerships between the market's key players to support the introduction of various biosimilars in the country are boosting the growth of Saudi Arabia's generic drugs market. In February 2022, Axantia Holding and Lupin Ltd. announced that they have entered into a License, Supply, and Technology Sharing agreement under which Axantia will market, register, and distribute biosimilar Pegfilgrastim Drug Products in various territories, including Algeria, Libya, Jordan, Sudan, Iraq, Lebanon, and Saudi Arabia. Pegfilgrastim has been indicated to reduce the incidences of febrile neutropenia and the duration of neutropenia in patients receiving chemotherapy. Lupin had earlier received acceptance from the US Food and Drug Administration (FDA) for review of their Biologics License Application (BLA) for their proposed biosimilar through a filing, with the help of the 351(k) pathway.
1. Project Scope and Definitions
2. Research Methodology
3. Executive Summary
4. Saudi Arabia Generic Drugs Market Outlook, 2017-2031F
4.1. Market Size Analysis & Forecast
4.1.1. By Value
4.1.2. By Volume
4.2. Market Share Analysis & Forecast
4.2.1. By Application
4.2.1.1. Neurovascular
4.2.1.2. Cardiovascular
4.2.1.3. Dermatology
4.2.1.4. Oncology
4.2.1.5. Diabetology
4.2.1.6. Respiratory
4.2.1.7. Others
4.2.2. By Type
4.2.2.1. Biosimilar Generics
4.2.2.2. Small Molecule Generics
4.2.3. By Brand
4.2.3.1. Branded Generic
4.2.3.2. Pure Generic
4.2.4. By Route of Administration
4.2.4.1. Oral
4.2.4.2. Injectable
4.2.4.3. Topical
4.2.4.4. Others
4.2.5. By Distribution Channel
4.2.5.1. Hospital Pharmacy
4.2.5.2. Retail Pharmacy
4.2.5.3. Online Pharmacy
4.2.6. By Region
4.2.6.1. Riyadh
4.2.6.2. Makkah
4.2.6.3. Eastern Region
4.2.6.4. Madinah
4.2.6.5. Rest of Saudi Arabia
4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
4.3.1. By Application
4.3.2. By Type
4.3.3. By Brand
4.3.4. By Route of Administration
4.3.5. By Distribution Channel
4.3.6. By Region
5. Demand Supply Analysis
6. Import and Export Analysis
7. Value Chain Analysis
8. Porter's Five Forces Analysis
9. PESTLE Analysis
10. Pricing Analysis
11. Market Dynamics
11.1. Market Drivers
11.2. Market Challenges
12. Market Trends and Developments
13. Regulatory Framework and Innovation
13.1. Bioavailability/Bioequivalence Studies
13.2. Regulatory Approvals
14. Patent Expiration
15. Case Studies
16. Competitive Landscape
16.1. Competition Matrix of Top 5 Market Leaders
16.2. SWOT Analysis for Top 5 Players
16.3. Key Players Landscape for Top 10 Market Players
16.3.1. Hikma Pharmaceuticals plc
16.3.1.1. Company Details
16.3.1.2. Key Management Personnel
16.3.1.3. Products and Services
16.3.1.4. Financials (As Reported)
16.3.1.5. Key Market Focus and Geographical Presence
16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
16.3.2. Novartis AG
16.3.3. Fresenius SE & Co. KGaA
16.3.4. Viatris Inc.
16.3.5. Aurobindo Pharma Saudi Arabia ltd.
16.3.6. Lupin Ltd.
16.3.7. Axantia Holding
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
17. Strategic Recommendations
18. About Us and Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security